Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy.

Autor: Gross S; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Ihlow J; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany. jana.ihlow@charite.de.; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany. jana.ihlow@charite.de.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Academy, BIH Charité Clinician Scientist Program, Charitéplatz 1, 10117, Berlin, Germany. jana.ihlow@charite.de., Busack L; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Adamiak K; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Schrezenmeier J; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Academy, BIH Charité Clinician Scientist Program, Charitéplatz 1, 10117, Berlin, Germany., Jesse J; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Schwarz M; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Flörcken A; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Vuong LG; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Rieger K; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Krönke J; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, German Cancer Consortium (DKTK), partner site, Berlin, Germany., le Coutre P; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Boldt V; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., von Brünneck AC; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Horst D; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Burmeister T; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Blau IW; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Keller U; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, German Cancer Consortium (DKTK), partner site, Berlin, Germany., Bullinger L; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, German Cancer Consortium (DKTK), partner site, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Westermann J; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany. joerg.westermann@charite.de.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany. joerg.westermann@charite.de.

Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Sep 16; Vol. 14 (1), pp. 160. Date of Electronic Publication: 2024 Sep 16.

Allogeneic stem cell transplantation for non-de novo AML or advanced myelodysplastic syndromes: influence of GvHD and donor lymphocyte infusions on long-term outcome.

Autor: Hemmati PG; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Pfeifer K; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Vuong LG; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Jehn CF; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Terwey TH; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., le Coutre P; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Dörken B; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Arnold R; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2018 Jan; Vol. 53 (1), pp. 101-103. Date of Electronic Publication: 2017 Oct 09.

Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome.

Autor: Hemmati PG; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany., Terwey TH; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany., Na IK; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany., Jehn CF; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany., le Coutre P; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany., Vuong LG; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany., Dörken B; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany., Arnold R; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany.

Publikováno v: European journal of haematology [Eur J Haematol] 2015 Dec; Vol. 95 (6), pp. 498-506. Date of Electronic Publication: 2015 Mar 24.

Synchronous tuberculosis, Epstein-Barr virus-associated lymphoproliferative disorder and cytomegalovirus infection in an allogeneic transplant recipient: a case report.

Autor: Ostendorf BN; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Augustenburger Platz 1, 13353 Berlin, Germany., Jehn CF; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Augustenburger Platz 1, 13353 Berlin, Germany., Vuong LG; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Augustenburger Platz 1, 13353 Berlin, Germany., Nogai H; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Augustenburger Platz 1, 13353 Berlin, Germany., Hemmati PG; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Augustenburger Platz 1, 13353 Berlin, Germany., Gebauer B; Department of Radiology, Charité University Medicine, Berlin, Germany., Penack O; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Augustenburger Platz 1, 13353 Berlin, Germany., Blau IW; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Augustenburger Platz 1, 13353 Berlin, Germany., Anagnostopoulos I; Institute of Pathology, Charité University Medicine, Berlin, Germany., Arnold R; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Augustenburger Platz 1, 13353 Berlin, Germany.

Publikováno v: SpringerPlus [Springerplus] 2014 Jun 02; Vol. 3, pp. 278. Date of Electronic Publication: 2014 Jun 02 (Print Publication: 2014).